small molecule

PANTOPRAZOLE SODIUM

Loss of exclusivity—loss of exclusivity

CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand name	PANTOPRAZOLE SODIUM
Active ingredient	PANTOPRAZOLE SODIUM
Strength	EQ 40MG BASE
Dosage form	FOR SUSPENSION, DELAYED RELEASE
Route	ORAL
Modality	Small molecule
FDA approval	March 2025
Marketing status	RX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.